Are you Dr. Raghav?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 36 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Dr. Kanwal Raghav, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Alabama, and Arizona. He is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
Albert Einstein Healthcare NetworkResidency, Internal Medicine, 2006 - 2009
Delhi University College of Medical SciencesClass of 2004
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2024 - 2026
OK State Medical License 2020 - 2026
TN State Medical License 2024 - 2026
AL State Medical License 2024 - 2025
GA State Medical License 2024 - 2025
LA State Medical License 2024 - 2025- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors Start of enrollment: 2017 Apr 07
- S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery Start of enrollment: 2017 Nov 27
- Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer Start of enrollment: 2019 Jan 29
Publications & Presentations
PubMed
- Mutational and co-mutational landscape of early onset colorectal cancer.Jumanah Yousef Alshenaifi, Guglielmo Vetere, Giulia Maddalena, Mahmoud Yousef, Michael G White
Biomarkers. 2025-01-09 - MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer.John H Strickler, Tanios Bekaii-Saab, Andrea Cercek, Volker Heinemann, Yoshiaki Nakamura
Future Oncology. 2024-12-26 - The Landscape of Circulating Tumor DNA (ctDNA) in Appendiceal Adenocarcinoma.Michael G White, Mohammad A Zeineddine, Eleanor A Fallon, Fadl A Zeineddine, Julia Dansby
Clinical Cancer Research. 2024-12-16
Press Mentions
MD Anderson Research Highlights for August 21, 2024August 21st, 2024- Confirmed Antitumor Activity with T-dXd for HER2-Positive Metastatic CRCAugust 16th, 2024
- MD Anderson Research Highlights: ASCO 2023 Special EditionMay 25th, 2023
- Join now to see all
